AOS to face competition
Wednesday, 25 June, 2008
Advanced Ocular Systems (ASX: AOS) will have to contend with a new competitor for its Triesence injectable triamcinolone acetonide anti-inflammatory, company directors warned the market yesterday.
The new product, known as Trivaris, is manufactured by Allergan. The FDA recently approved the drug for sale.
It will be in direct competition with Triesence, which was developed by AOS and is sold under license through Alcon.
The potential effect on the company's royalties revenues is currently unclear, AOS said.
Injectable triamcinolone acetonide is mainly used to treat inflammation of the eyes and other similar ocular diseases and disorders.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
